Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31055681 | 0.84 | SOS1 (0.49) | SOS1KDM4ECYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18031885 | 0.84 | ALDH1A1 (0.44) | SOS1KDM4EGAACYP3A4KMT2A | |
| SCHEMBL5853128 | 0.84 | SOS1 (0.49) | SOS1KDM4EGAAKMT2AALDH1A1 | |
| SCHEMBL19971599 | 0.84 | SOS1 (0.49) | SOS1KDM4ECYP1A2CYP2C19CYP2D6 | |
| SCHEMBL9223895 | 0.84 | KDM4E (0.47) | SOS1KDM4ECYP1A2CYP2C19CYP2D6 | |
| SCHEMBL18000485 | 0.83 | PLK1 (0.43) | KDM4EGAAPOLBKMT2AHPGD | |
| SCHEMBL25308574 | 0.82 | CA12 (0.49) | SOS1KDM4ECYP1A2CYP2C19GAA | |
| SCHEMBL1822622 | 0.82 | GAA (0.48) | KDM4ECYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL21817258 | 0.82 | SOS1 (0.48) | SOS1GAAPOLBALDH1A1TSHR | |
| SCHEMBL31712140 | 0.82 | SOS1 (0.40) | SOS1KDM4ECYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3617205-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3617205-B1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORP (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-113004278-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-107438607-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20200306256-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2020-10-01 | — | — | US | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| WO-2016134320-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244449-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160244449-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139145-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306256-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | SOS1 1738/4885KDM4E 269/4885CYP1A2 1250/4885 |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | FGFR3, FGFR1, FGFR4 | SOS1 2009/4885KDM4E 1569/4885CYP1A2 2472/4885 |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | SOS1 2124/4885KDM4E 1548/4885CYP1A2 2564/4885 |
| US-11173162-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR3, FGFR1 | SOS1 1879/4885KDM4E 451/4885CYP1A2 582/4885 |
| US-20160244449-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR3, FGFR1 | SOS1 1738/4885KDM4E 269/4885CYP1A2 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.